Stock Markets January 27, 2026

Helix Acquisition Corp. III Completes $172.5 Million IPO, Places Proceeds in Trust

SPAC sponsored by Helix Holdings III LLC targets healthcare deals; concurrent private placement generates $4.975 million in gross proceeds

By Nina Shah
Helix Acquisition Corp. III Completes $172.5 Million IPO, Places Proceeds in Trust

Helix Acquisition Corp. III completed its initial public offering on January 26, selling 17.25 million Class A ordinary shares at $10 per share to raise $172.5 million in gross proceeds, the company said. The offering included 2.25 million shares issued through the full exercise of the underwriters' over-allotment option. Concurrently, the sponsor purchased 497,500 Class A ordinary shares in a private placement at $10 per share, generating $4.975 million in additional gross proceeds. The company is a special purpose acquisition company formed to pursue mergers or acquisitions in healthcare or healthcare-related industries, and has placed the proceeds in trust.

Key Points

  • Helix Acquisition Corp. III sold 17.25 million Class A ordinary shares at $10 each on January 26, producing $172.5 million in gross proceeds; the offering included 2.25 million shares from the underwriters' over-allotment option.
  • A concurrent private placement of 497,500 Class A ordinary shares at $10 per share to Helix Holdings III LLC generated an additional $4.975 million in gross proceeds.
  • The SPAC, sponsored by Helix Holdings III LLC (an affiliate of Cormorant Asset Management) and led by CEO and chairperson Bihua Chen and CFO/COO Caleb Tripp, will pursue mergers or acquisitions in healthcare or healthcare-related industries; proceeds were placed in trust and an audited balance sheet will be filed as an exhibit to a Form 8-K.

Helix Acquisition Corp. III finalized its initial public offering on January 26, raising $172.5 million through the sale of 17.25 million Class A ordinary shares, priced at $10 per share, according to a company statement. The public offering included the full exercise of the underwriters' over-allotment option, representing 2.25 million shares.

The proceeds reported are gross amounts and have not been reduced by underwriting fees or other offering expenses. The special purpose acquisition company was formed to pursue mergers or acquisitions in healthcare or healthcare-related industries. The firm is sponsored by Helix Holdings III LLC, an affiliate of Cormorant Asset Management.

Management named in the filing includes Bihua Chen serving as chief executive officer and chairperson, and Caleb Tripp serving as chief financial officer and chief operating officer.

Concurrent with the closing of the IPO, Helix Acquisition Corp. III completed a private placement in which Helix Holdings III LLC purchased 497,500 Class A ordinary shares at $10 per share, producing additional gross proceeds of $4.975 million.

The company's public shares began trading on The Nasdaq Global Market under the ticker symbol "HLXC" on January 23. Leerink Partners and Oppenheimer & Co. acted as joint bookrunning managers for the offering.

A total of $172.5 million from the IPO and simultaneous private placement was placed in trust. The company indicated it will file an audited balance sheet reflecting receipt of proceeds as an exhibit to a Form 8-K with the Securities and Exchange Commission.

The filing notes that the amounts cited are gross proceeds before customary deductions and that the vehicle's stated focus is transactions in healthcare or healthcare-related industries. Aside from identifying its sponsor and senior officers, the statement provides no additional detail on prospective targets or proposed transaction timelines.


Context and next steps

With placement of the proceeds in trust and a Form 8-K exhibit forthcoming that will include an audited balance sheet, Helix Acquisition Corp. III has completed the principal financial steps that typically follow a SPAC offering. The statement does not provide further specifics on planned acquisitions or a timetable for deploying trust funds into a qualifying transaction.

Risks

  • Net proceeds will be reduced by underwriting fees and other offering expenses, which could lower available capital - this impacts the SPAC and potential healthcare targets.
  • The filing does not identify specific acquisition targets or a timeline for a qualifying transaction, creating uncertainty about when trust funds will be deployed - this affects prospective healthcare merger counterparties and investors.
  • The company's next formal disclosure will be an audited balance sheet filed as an exhibit to a Form 8-K; until that filing is made available, the market has limited audited information on receipt and composition of the proceeds.

More from Stock Markets

Australian Shares Finish Higher as Gold, IT and Mining Stocks Lead Gains Feb 3, 2026 Global Consultancies Adopt Riskier Workarounds in China Amid Sanctions and New Data Rules Feb 3, 2026 Indian equities rally after U.S. agrees tariff reductions in trade accord Feb 2, 2026 SiTime Nears Acquisition of Renesas Timing Business in Potential $3 Billion Deal Feb 2, 2026 Tesla Debuts New All-Wheel Drive Model Y Trim in U.S.; Premium Option Also Launched Feb 2, 2026